Physician profile
Wasim Dar
NPI 1477501039
$5,702.92
in general payments reported to CMS, 2019-2025
15 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $1,259 · 2021: $363 · 2022: $1,361 · 2023: $649 · 2024: $162 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Consulting Fee: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.72 |
| Consulting Fee | $520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox LTD | $3,300.00 | 2019-2022 | |
| Baxter Healthcare | $572.66 | 2023 | Tisseel, Floseal |
| Intuitive Surgical, INC. | $375.09 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $349.35 | 2019-2025 | Envarsus |
| Covidien LP | $325.00 | 2020 | |
| Dilon Technologies, INC. | $165.77 | 2025 | Hemoblast Bellows |
| Stryker Corporation | $140.63 | 2022 | |
| Gilead Sciences, INC. | $127.35 | 2024 | Livdelzi |
| Dynavax Technologies Corporation | $122.53 | 2021 | |
| Eisai INC. | $93.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.79 | 2023-2025 | |
| Acell, INC. | $34.23 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.01 | 2025 | |
| Merck Sharp & Dohme LLC | $18.65 | 2025 | Prevymis |
| Mallinckrodt Hospital Products INC. | $15.50 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasim Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.